Division of Nephrology, University of Campania, Piazza L. Miraglia, 1, 80138, Naples, Italy.
Nephrology and Dialysis Unit, Parodi-Delfino Hospital, Colleferro, Rome, Italy.
J Nephrol. 2018 Oct;31(5):653-664. doi: 10.1007/s40620-018-0502-6. Epub 2018 Jun 7.
Chronic hyperkalemia is a major complication of chronic kidney disease (CKD) that occurs frequently, heralds poor prognosis, and necessitates careful management by the nephrologist. Current strategies aimed at prevention and treatment of hyperkalemia are still suboptimal, as evidenced by the relatively high prevalence of hyperkalemia in patients under stable nephrology care, and even in the ideal setting of randomized trials where best treatment and monitoring are mandatory. The aim of this review was to identify and discuss a range of unresolved issues related to the management of chronic hyperkalemia in non-dialysis CKD. The following topics of clinical interest were addressed: diagnosis, relationship with main comorbidities of CKD, therapy with inhibitors of the renin-angiotensin-aldosterone system, efficacy of current dietary and pharmacological treatment, and the potential role of the new generation of potassium binders. Opinion-based answers are provided for each of these controversial issues.
慢性高钾血症是慢性肾脏病(CKD)的一种主要并发症,其发病率高,预示着预后不良,需要肾病医生进行仔细的管理。目前旨在预防和治疗高钾血症的策略仍不尽人意,因为在稳定的肾病护理下的患者中,高钾血症的相对高发率,甚至在理想的随机试验环境中,最佳的治疗和监测也是强制性的,都证明了这一点。本综述的目的是确定和讨论与非透析性 CKD 慢性高钾血症管理相关的一系列未解决的问题。以下是临床关注的主题:诊断、与 CKD 主要合并症的关系、肾素-血管紧张素-醛固酮系统抑制剂的治疗、当前饮食和药物治疗的疗效,以及新一代钾结合剂的潜在作用。针对这些有争议的问题,提供了基于观点的答案。